Company Profile
Galectin Therapeutics Stock Price, News & Analysis
- Ticker:
- GALT
- Exchange:
- NASDAQ
- Sector:
- Biotechnology
- Location:
- United States
Stock performance
4.60 USD (+13.30%)
Close
Last updated: July 13, 2026 at 00:00
267.38M USD
Market cap
Why the stock is moving
GALT is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Company overview
Business overview
Galectin Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Galectin Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Galectin Therapeutics follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Galectin Therapeutics sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Future catalysts
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
Zimmer Biomet Names Chintan Desai President of Asia Pacific Region
ZBH · Source: Zimmer Biomet
- 02
Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results
ZBH · Source: Zimmer Biomet
- 03
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma
BMY · Source: BMYBristol-Myers Squibb Company
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Galectin Therapeutics (GALT)?
Galectin Therapeutics (GALT) most recently closed at 4.60 USD, a +13.30% move versus the previous session.
What is the market cap of Galectin Therapeutics (GALT)?
Galectin Therapeutics currently has a market capitalization of 267.38M USD on BioPharmSignal.
What does Galectin Therapeutics do?
Galectin Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
On which exchange is GALT stock listed?
Galectin Therapeutics (GALT) is associated with NASDAQ, United States, Biotechnology.
What is Galectin?
Galectin Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Which conditions is Galectin Therapeutics targeting with Galectin?
Galectin Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
What is Therapeutics?
Galectin Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.